The Rechallenge of ADCs in MBC Patients
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: ADC
- Registration Number
- NCT05571618
- Lead Sponsor
- Fudan University
- Brief Summary
To investigate the efficacy and safety of ADC rechallenge
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- age > 18 years old.
- Diagnosed with Metastatic Breast Cancer.
- Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
- Patients plan to or have received ADCs for the second or more time.
- Complete medical history was available.
Read More
Exclusion Criteria
- Medical history was incomplete
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group1 ADC -
- Primary Outcome Measures
Name Time Method PFS 6 weeks Progression free survival
- Secondary Outcome Measures
Name Time Method Adverse events 6 weeks Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
DoR 6 weeks Duration of Response
ORR 6 weeks Objective Response Rate
OS 6 weeks Overall Survival
CBR 6 weeks Clinical Benefit Rate
Trial Locations
- Locations (1)
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China